Multi- and single-target agents for major psychiatric diseases: Therapeutic opportunities and challenges

Current Opinion in Investigational Drugs

Volumn 9, Issue 1, 2008, Pages 28-36

  Wong, E H F ^a   Nikam, S S ^b,c   Shahid, M ^d  

^a ASTRAZENECA   (United Kingdom)

^b Nycomed Pharma Pvt Ltd   (India)

^c PFIZER INC   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Depression; Multi target agent; Polypharmacy; Psychopharmacological; Schizophrenia; Single target agent

Indexed keywords

AGOMELATINE; APREPITANT; BENZODIAZEPINE DERIVATIVE; BIOLOGICAL MARKER; CHLORPROMAZINE; CLOZAPINE; DIZOCILPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; G PROTEIN COUPLED RECEPTOR; HALOPERIDOL; HISTAMINE H3 RECEPTOR; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; MUSCARINIC M1 RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NARCOTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PETHIDINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; UNINDEXED DRUG; VENLAFAXINE; VOLINANSERIN; ZIPRASIDONE;

AGONIST; AGRANULOCYTOSIS; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HEART MUSCLE CONDUCTION DISTURBANCE; HEMODYNAMICS; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; INSOMNIA; METABOLIC SYNDROME X; NAUSEA; NERVOUSNESS; POLYPHARMACY; RECEPTOR BLOCKING; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG DESIGN; HUMANS; SCHIZOPHRENIA;

EID: 38049040370     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Fishman PA, Stang PE, Hogue SL: Impact of comorbid attention deficit disorder on the direct medical costs of treating adults with depression in managed care. J Clin Psychiatry (2007) 68(2):248-253.
2. Shoval G, Zalsman G, Nahshoni E, Weizman A: The use of illicit substances in adolescent schizophrenia inpatients. Int J Adolesc Med Health (2006) 18(4):643-648.
3. Roth BL, Sheffler DJ, Kroeze WK: Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov (2004) 3(4):353-359. • This paper provides a compelling insight into how agents working on multiple targets should be put into context of intended utility rather than viewed as 'dirty drugs'.
4. Morphy R, Kay C, Rankovic Z: From magic bullets to designed multiple ligands. Drug Disc Today (2004) 9(15):641-651.
5. Roth BL: Contributions of molecular biology to antipsychotic drug discovery: Promises fulfilled or unfulfilled? Dialogues Clin Neurosci (2006) 8(3):303-309. • This is a balanced review highlighting the impact of the molecular biology revolution on drug discovery and identification of therapeutically useful molecules for the treatment of schizophrenia.
6. Nebert DW, Jorge-Nebert L, Vesell ES: Pharmacogenomics and "individualized drug therapy", high expectations and disappointing achievements. Am J Pharmacogenomics (2003) 3(6):361-370.
7. Millan MJ: Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther (2006) 110(2):135-370. •• This is an exceptional review describing, in a thoughtful and comprehensive manner, how all antidepressants, by default or by intention, are multi-target agents.
8. Morphy R, Rankovic Z: Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem (2005) 48(21):6523-6543. •• An excellent paper summarizing the medicinal chemistry perspective on the therapeutic utility and technological challenges associated with designing multi-target compounds.
9. Preskorn SH, Lacey RL: Polypharmacy: When is it rational? J Psychiatr Pract (2007) 13(2):97-105.
10. Youdim MBH, Buccafusco JJ: Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci (2005) 26(1):27-35. • This paper presents a rationale on potential clinical benefits of multitarget approaches toward the management of multiple symptom demands of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease.
11. Van der Schyf CJ, Gal S, Geldenhuys WJ, Youdim MBH: Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert Opin Invest Drugs (2006) 15(8):873-886.
12. Christiaans JAM, Timmerman H: Cardiovascular hybrid drugs: Combination of more than one pharmacological property in one single molecule. Eur J Pharm Sci (1996) 4(1):1-22.
13. Zerkak D, Dougados M: Benefit/risk of combination therapies. Clin Exp Rheumatol (2004) 22(5 Suppl 35):S71-S76.
14. Ban TA: The role of serendipity in drug discovery. Dialogues Clin Neurosci (2006) 8(3):335-344.
15. 3H]diazepam binding. Proc Natl Acad Sci USA (1977) 74(9):3805-3809.
16. Fuller RW, Wong DT, Robertson DW: Fluoxetine, a selective inhibitor of serotonin uptake. Med Res Rev (1991) 11(1):17-34.
17. 1A receptor antagonist, WAY-100635. Eur J Pharmacol (1995) 281(1):81-88.
18. 1) antagonists. Trends Pharmacol Sci (1999) 20(12):485-490.
19. Wong EHF, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iversen LL: The anticonvulsant MK-801 is a potent N-methyl-D- aspartate antagonist. Proc Natl Acad Sci USA (1986) 83(18):7104-7108.
20. 2A serotonin receptors selectively in primate brain. Neuropharmacology (1998) 37(9):1147-1158.
21. Floresco SB, Geyer MA, Gold LH, Grace AA: Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. Schizophr Bull (2005) 31(4):888-894.
22. Cryan JF, Slattery DA: Animal models of mood disorders: Recent developments. Curr Opin Psychiatry (2007) 20(1):1-7.
23. 4 receptor agonist. Psychopharmacology (2006) 188(2):244-251.
24. 2 receptor in schizophrenia. Expert Opin Ther Targets (2006) 10(4):515-531.
25. Creese I, Burt DR, Synder SH: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science (1976) 192(4238):481-483.
26. Roth BL, Sheffler DJ, Potkin SG: Atypical antipsychotic drug actions: Unitary or multiple mechanisms for 'atypicality'? Clin Neurosci Res (2003) 3(1):108-117.
27. Duman RS, Monteggia LM: A neurotrophic model for stress-related mood disorders. Biol Psychiatry (2006) 59(12):1116-1127.
28. 1 receptor antagonists under investigation for the treatment of affective disorders. Expert Opin Invest Drugs (2006) 15(5):479-486.
29. de Paulis T: M-100907 (Aventis). Curr Opin Investig Drugs (2001) 2(1):123-132.
30. 4 Dopamine Antagonist Group. Arch Gen Psychiatry (1997) 54(6):567-572. Erratum in: Arch Gen Psychiatry (1997) 54(12):1080.
31. Meltzer HY, Arvanitis L, Bauer D, Rein W, Meta-Trial Study Group: Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry (2004) 161(6):975-984.
32. O'Connell, Roblin D: Translational research in the pharmaceutical industry: From bench to bedside. Drug Disc Today (2006) 11(17-18):833-838.
33. Philipp M, Hein L: Adrenergic receptor knockout mice: Distinct functions of 9 receptor subtypes. Pharmacol Ther (2004) 101(1):65-74.
34. Shelton RC, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, Case M, Briggs SD, Tollefson GD: Olanzapine/fluoxetine combination for treatment-resistant depression: A controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry (2005) 66(10):1289-1297.
35. Marder SR: The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues Clin Neurosci (2006) 8(1):109-113.
36. Insel TR: Beyond efficacy: The STAR*D trial. Am J Psychiatry (2006) 163(1):5-7.
37. Shayegan DK, Stahl SM: Atypical antipsychotics: Matching receptor profile to individual patient's clinical profile. CNS Spectr (2004) 9(10 Suppl 11):6-14. • This paper describes the future of discovery strategies in atypical antipsychotics. Phenotyping and genotyping will decide what mechanism(s) will best treat a particular patient.
38. 1A affinity and minimal extrapyramidal side-effect liability. In: Advances in Medicinal Chemistry. Maryanoff BE, Maryanoff CA (Eds), JAI Press Inc, Stamford, CT, USA (1995) 3:1-55.
39. 2 receptors. Prog Neuro Psychopharmacol Biol Psychiatry (2003) 27(7):1081-1090.
40. Baldessarini RJ, Frankenburg FR: Clozapine. A novel antipsychotic agent. N Engl J Med (1991) 324(11):746-774.
41. Faber HJ, Smit JA, van de Loosdrecht AA: Clozapine induced agranulocytosis: Hypothesis on immune-mediated pathogenesis and the role of haematopoietic growth factors. Neth J Med (1999) 55(2):86-87.
42. Meltzer HY, Li Z, Kaneda Y, Ichikawa J: Serotonin receptors: Their key role in drugs to treat schizophrenia. Prog Neuro Psychopharmacol Biol Psychiatry (2003) 27(7):1159-1172.
43. 2A receptor blockade. CNS Neurol Disord - Drug Targets (2006) 5(4):445-452.
44. Newcomer JW: Metabolic risk during antipsychotic treatment. Clin Ther (2004) 26(12):1936-1946.
45. Glassman AH: Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry (2005) 66(Suppl 6):5-10.
46. Lieberman JA: Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Arch Gen Psychiatry (2006) 63(10):1069-1072.
47. Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR, Nguyen HQ, Dawson LA, Barrett JE et al: WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta[b][1,4] diazepino [6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther (2007) 320(1):486-496.
48. Delgado P, Moreno FA: Role of norepinephrine in depression. J Clin Psychiatry (2000) 61(Suppl 1):5-12.
49. Hefti FF: Current antidepressant drugs and the monoamine hypothesis. In: Drug Discovery for Nervous System Diseases (2004) 7:119-122. • This paper gives a good background of how chemical templates evolved over the last 50 years starting from tricyclic antidepressants.
50. Mace S, Taylor D: Selective serotonin reuptake inhibitors: A review of efficacy and tolerability in depression. Expert Opin Pharmacother (2000) 1(5):917-933.
51. Delgado PL, Michaels T: Reboxetine: A review of efficacy and tolerability. Drugs Today (1999) 35(9):725-737.
52. Stahl SM, Gardy MM, Moret C, Briley M: SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr (2005) 10(9):732-747.
53. Westenberg HGM: Pharmacology of antidepressants: Selectivity or multiplicity. J Clin Psychiatry (1999) 60(Suppl 9):34-41. •• An important, early contribution describing the evolution of antidepressant drug discovery and addressing the relative therapeutic merit of compounds with a high target selectivity or multireceptor profile.
54. 2- selective adrenoceptor antagonist Org 3770 (mirtazapine remeron) enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol (1995) 10:107S-118S.
55. Stahl SM, Grady MM: Differences in mechanism of action between current and future antidepressants. J Clin Psychiatry (2003) 64(Suppl 13):13-17.
56. Giannetti VJ: Adherence with antidepressant medication. Manag Care (2004) 13(6 Suppl):42-47.
57. Balon R: SSRI-associated sexual dysfunction. Am J Psychiatry (2006) 163(9):1504-1509.
58. Zupancic M, Guilleminault C: Agomelatine: A preliminary review of a new antidepressant. CNS Drugs (2006) 20(12):981-992.
59. Paul IA, Skolnick PL: Glutamate and depression. Ann NY Acad Sci (2003) 1003:250-272.
60. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK: A randomized trial of an N-methyl- D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 63(8):856-864.
61. Tunnicliff G, Malatynska E: Central GABAergic systems and depressive illness. Neurochem Res (2003) 28(6):965-976.
62. Van Broekhoven F, Verkes RJ: Neurosteroids in depression: A review. Psychopharmacology (2003) 165(2):97-110.
63. Valentino RJ, Commons KG: Peptides that fine-tune the serotonin system. Neuropeptides (2005) 39(1):1-8.
64. Abou-Saleh MT: Neuroimaging in psychiatry: An update. J Psychosom Res (2006) 61(3):289-293.
65. Wermuth CG: Selective optimization of side activities: Another way for drug discovery. J Med Chem (2004) 47(6):1303-1314.
66. Rees DC, Congreve M, Murray CW, Carr R: Fragment-based lead discovery. Nat Rev Drug Discov (2004) 3(8):660-672.
67. Morphy R, Rankovic Z: Fragments, network biology and designing multiple ligands. Drug Disc Today (2007) 12(3-4):156-160.
68. Booth B, Zemmel R: Quest for the best. Nat Rev Drug Discov (2003) 2(10):838-841.
69. Shahid M, Walker GB, Zorn SH, Wong EHF: Asenapine: A novel psychopharmacologic agent with a unique human receptor binding signature. J Psychopharmacol (2007): in press.